# US 2025/0152608 A1 · Contraceptive methods with improved pearl index

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152608 A1
- Document ID: US20250152608A1
- Status: Published application
- Kind: A1
- Application number: 19/025,832
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2022-02-10
- Assignees: Estetra Srl
- Applicants: Estetra Srl
- Inventors: Jean-Michel FOIDART; Maud JOST
- Web page: https://patentgrep.com/patent/US20250152608A1

## CPC

- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are methods of providing contraception in a woman having a BMI ≥30.0 kg/m2, comprising: selecting a woman determined to have a BMI ≥30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI ≥30.0 kg/m2, comprising: selecting a woman determined to have a BMI ≥30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive day.

## Claims

### Claim 1

A method of contraception that achieves a Pearl Index of <5 in women having a BMI ≥30.0 kg/m2, comprising:
selecting a woman determined to have a BMI ≥30.0 kg/m2, and then
orally administering to the selected woman a therapeutically effective amount of an estetrol component comprising an estetrol moiety at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg,
wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.

### Claim 2 (depends on 1)

The method of claim 1, further comprising, prior to the selecting, calculating the BMI of the woman from a measured height and weight of the woman.

### Claim 3 (depends on 1)

The method of claim 1, wherein the selecting comprises selecting a woman determined to have a BMI ≥30.0 kg/m2 and ≤35.0 kg/m2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method achieves a Pearl Index of <3.5.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method achieves a Pearl Index of <3.

### Claim 6 (depends on 1)

The method of claim 1, wherein the woman is 16-25 years old.

### Claim 7 (depends on 1)

The method of claim 1, wherein the woman is 16-35 years old.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method comprises 12 cycles of daily administration of the estetrol component and drospirenone on 24 consecutive days, followed by a hormone-free period of 4 consecutive days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method comprises 12 consecutive 28-day cycles of daily administration of the estetrol component and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of the estetrol component and drospirenone on consecutive days 25-28.

### Claim 10 (depends on 1)

The method of claim 1, wherein the estetrol component is estetrol monohydrate.

### Claim 11 (depends on 1)

The method of claim 1, wherein the estetrol component is estetrol monohydrate and is administered at a daily dose of 15 mg, based on the estetrol moiety, and the drospirenone is administered at a daily dose of 3 mg.

### Claim 12

A method of contraception that achieves a Pearl Index of <5 in women having a BMI ≥30.0 kg/m2, comprising:
selecting a woman determined to have a BMI ≥30.0 kg/m2, and then
orally administering to the selected woman a therapeutically effective amount of estetrol monohydrate at a daily dose of 15 mg, and drospirenone at a daily dose of 3 mg,
wherein the method comprises daily administration of estetrol monohydrate and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.

### Claim 13 (depends on 12)

The method of claim 12, further comprising, prior to the selecting, calculating the BMI of the woman from a measured height and weight of the woman.

### Claim 14 (depends on 12)

The method of claim 12, wherein the selecting comprises selecting a woman determined to have a BMI ≥30.0 kg/m2 and ≤35.0 kg/m2.

### Claim 15 (depends on 12)

The method of claim 12, wherein the method achieves a Pearl Index of <3.5.

### Claim 16 (depends on 12)

The method of claim 12, wherein the method achieves a Pearl Index of <3.

### Claim 17 (depends on 12)

The method of claim 12, wherein the woman is 16-25 years old.

### Claim 18 (depends on 12)

The method of claim 12, wherein the woman is 16-35 years old.

### Claim 19 (depends on 12)

The method of claim 12, wherein the method comprises 12 cycles of daily administration of estetrol monohydrate and drospirenone on 24 consecutive days, followed by a hormone-free period of 4 consecutive days.

### Claim 20 (depends on 12)

The method of claim 12, wherein the method comprises 12 consecutive 28-day cycles of daily administration of estetrol monohydrate and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of estetrol monohydrate and drospirenone on consecutive days 25-28.

### Claim 21

A method of contraception that achieves a Pearl Index of <3.5 in women having a BMI≥30.0 kg/m2, comprising:
selecting a woman determined to have a BMI ≥30.0 kg/m2, and then
orally administering to the selected woman a therapeutically effective amount of estetrol monohydrate at a daily dose of 15 mg, and drospirenone at a daily dose of 3 mg,
wherein the method comprises 12 cycles of daily administration of estetrol monohydrate and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.

### Claim 22 (depends on 21)

The method of claim 21, wherein the woman is 16-25 years old.

### Claim 23 (depends on 21)

The method of claim 21, wherein the woman is 16-35 years old.
